The association says a provision requiring MACs to independently review LCDs from other jurisdictions before adoption is critical to the legislation.

The financing will go toward driving adoption of the company's technology, which can distinguish bacterial infections from viral ones, and other purposes.

The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.

MRM will develop immuno-MALDI mass spec assays to key cancer signaling proteins and test them in 100 breast and colorectal cancer samples provided by Exactis.